Research progress in the effects of intraocular pressure-lowering drugs on the ocular surface of glaucoma patients
10.3980/j.issn.1672-5123.2023.11.11
- VernacularTitle:降眼压药物对青光眼患者眼表影响的研究进展
- Author:
Jie YANG
1
;
Yuan HE
1
;
Ying LIU
1
;
Rui SHI
1
;
Yao LU
1
;
Dan-Dan LIU
1
;
Xiao-Yu GONG
1
Author Information
1. Xi'an Medical University, Xi'an 710021, Shaanxi Province, China; Department of Ophthalmology, the Second Affiliated Hospital of Xi'an Medical University, Xi'an 710038, Shaanxi Province, China; Department of Ophthalmology, Shaanxi Provincial People's Hospital, Xi'an 710068, Shaanxi Province, China
- Publication Type:Journal Article
- Keywords:
topical antiglaucoma medication;
glaucoma;
ocular surface disease
- From:
International Eye Science
2023;23(11):1826-1830
- CountryChina
- Language:Chinese
-
Abstract:
Glaucoma is a chronic optic neuropathy that affects the retinal ganglion cells, characterized by optic disc atrophy, visual field defects, and visual acuity loss. Since glaucoma is a chronic disease, long-term use of topical intraocular pressure-lowering medications often leads to ocular surface diseases, thus reducing medication adherence and ultimately affecting treatment efficacy. Currently, topical intraocular pressure-lowering medications include prostaglandin derivatives, β-adrenergic blockers, α-adrenergic agonists, topical carbonic anhydrase inhibitors, and cholinergic drugs. This article provides a comprehensive review of the effects and related mechanisms of these five antiglaucoma medications on the ocular surface of glaucoma patients and offers preventative measures for the protection of ocular surface in glaucoma patients.
